Biophysical technologies for understanding circulating tumor cell biology and metastasis

Su, Derrick W.; Nieva, Jorgé

doi:10.21037/tlcr.2017.05.08

Cited by 18 publications

(9 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, while the CellSearch technology has been useful, it relies on high levels of EpCAM expression on the CTCs. Therefore, methods still need to be developed to detect tumor cells with downregulated epithelial proteins [60].…”

Section: Discussionmentioning

confidence: 99%

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Agashe

Kurzrock

2020

Cancers

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are cells that are shed from tumors into the bloodstream. Cell enrichment and isolation technology as well as molecular profiling via next-generation sequencing have allowed for a greater understanding of tumor cancer biology via the interrogation of CTCs. CTC detection can be used to predict cancer relapse, progression, and survival; evaluate treatment effectiveness; and explore the ex vivo functional impact of agents. Detection methods can be by either immunoaffinity (positive or negative enrichment strategies) or biophysical strategies. CTC characterization, which is performed by DNA, RNA, and/or protein techniques, can predict metastatic potential. Currently, CTC-derived explant models may mimic patient response to chemotherapy and help with studying druggable targets and testing treatments. The Food and Drug Administration has cleared a CTC blood test to enumerate CTCs derived from breast, prostate, and colorectal cancers. In conclusion, liquid biopsies via CTCs provide a non-invasive way to obtain important diagnostic, prognostic, and predictive information in patients with cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Agashe

Kurzrock

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…CELLSEARCH ® is an FDA approved test for capturing and enumerating CTCs. This method uses ferrofluid reagent, which consists of particles with a magnetic core surrounded by a polymeric layer coated with antibodies targeting the Epithelial cell adhesion molecule (EpCAM) antigen, for capturing CTCs [64]. The CTC chip, a microfluidic device is one of the techniques used for isolation of CTCs.…”

Section: Methodsmentioning

confidence: 99%

Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology

Mathai

Vidya

Reddy

et al. 2019

JCM

111

103

View full text Add to dashboard Cite

Liquid biopsy is a technique that utilizes circulating biomarkers in the body fluids of cancer patients to provide information regarding the genetic landscape of the cancer. It is emerging as an alternative and complementary diagnostic and prognostic tool to surgical biopsy in oncology. Liquid biopsy focuses on the detection and isolation of circulating tumor cells, circulating tumor DNA and exosomes, as a source of genomic and proteomic information in cancer patients. Liquid biopsy is expected to provide the necessary acceleratory force for the implementation of precision oncology in clinical settings by contributing an enhanced understanding of tumor heterogeneity and permitting the dynamic monitoring of treatment responses and genomic variations. However, widespread implementation of liquid biopsy based biomarker-driven therapy in the clinical practice is still in its infancy. Technological advancements have resolved many of the hurdles faced in the liquid biopsy methodologies but sufficient clinical and technical validation for specificity and sensitivity has not yet been attained for routine clinical implementation. This article provides a comprehensive review of the clinical utility of liquid biopsy and its effectiveness as an important diagnostic and prognostic tool in colorectal, breast, hepatocellular, gastric and lung carcinomas which were the five leading cancer related mortalities in 2018.

show abstract

“…69 " CTC-chip " test that developed by Chikaishi et al demonstrated better performance than CELLSEARCH®test that is approved by the United States Food and Drug Administration (US FDA). 70,71 Chest pain is common and usually heavy and dull and sometime called a " dragging " sensation, 5,72 Breathlessness is also common and is usually due to a pleural effusion that is identified in about 70 % of MPM patients in early stage of disease. 73 Other clinical features include anorexia, weight loss, malaise, sweats, and fatigue.…”

Section: Clinical Manifestations Investigation and Diagnosismentioning

confidence: 99%

Malignant pleural mesothelioma: current perspectives

Cheepsattayakorn¹,

Cheepsattayakorn²,

Manosoontorn³

et al. 2020

JLPRR

View full text Add to dashboard Cite

The objectives of this study are to review epidemiology, novel methods of detection, novel diagnostics, and novel therapeutic options of malignant pleural mesothelioma (MPM) in the literature that were published between 1977 and 2019. Malignant pleural mesothelioma, associated with prolonged respirable-asbestos-fiber exposure is a rare cancer with constantly increasing incidence and poor prognosis due to lacking the effective treatment options. The median survival ranges from 8 to 14 months. Sarcomatoid histological subtype has the worst prognosis. Video-assisted thoracoscopy plus mediastinoscopy is the current gold standard for staging malignant pleural mesothelioma and is superior to computerized tomography of the chest for assessing the tumor size and suspected nodal metastases. Several circulating biomarkers are detected in MPM patients, such as mesothelin, osteopontin, fibulin-3, high mobility group B1, vascular endothelial growth factor, reactive oxygen species, reactive nitrogen species, micro-ribonucleic acids, tumor deoxyribonucleic acid, etc.Surgery is controversial and restricted to patients with early stage disease and good functional status. There is still no curative treatment whereas chemotherapy is the only treatment modality that improve patients’ survival. Radiotherapy is beneficial as a palliative treatment and an adjuvant to chemotherapy and surgery in the context of trimodality treatment. In conclusion, there is potential for the development of biomarkers and radiological imaging in the years to come. Several novel therapeutic options are under studied and it is likely to involve highly personalized treatment. Its incidenceis expected to decrease in the next decade.

show abstract

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Cited by 18 publications

References 84 publications

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology

Malignant pleural mesothelioma: current perspectives

Contact Info

Product

Resources

About